Journal Watch · Journal of Medicinal Chemistry · 2026
Discovery and Characterization of GLPG3808, a PAPD5/7 Inhibitor for Suppression of Hepatitis B Viral Infections.
Progression was halted after neurological findings in a 13-week toxicological study in rat.
TL;DR
Progression was halted after neurological findings in a 13-week toxicological study in rat.
Key findings
- The effort culminated with the extremely potent preclinical candidate GLPG3808, which was active in an animal model of HBV infection.
- Progression was halted after neurological findings in a 13-week toxicological study in rat.
What they did
In this context, we focused on PAPD5/7 inhibitors as effective HBsAg suppressors. Leveraging a 2-oxo-5<i>H</i>-chromeno[4,3-<i>b</i>]pyridine template, we exploited a chemical enablement strategy for broad combinatorial explorations. This rapidly led to the identification of optimal groups not seen in other PAPD5/7 inhibitors.
Full abstract (original)
Background: Hepatitis B virus (HBV) is the most common and severe liver infection, and approximately 260 million people suffer from chronic hepatitis B infection, which can lead to life-threatening conditions such as cirrhosis and hepatocellular carcinoma. Treatment of the infection resulting in sustained clearance of hepatitis B surface antigen (HBsAg) is considered as "functional cure". Although current treatments effectively reduce the viral load, few agents have achieved HBsAg reduction.
What they did: In this context, we focused on PAPD5/7 inhibitors as effective HBsAg suppressors. Leveraging a 2-oxo-5<i>H</i>-chromeno[4,3-<i>b</i>]pyridine template, we exploited a chemical enablement strategy for broad combinatorial explorations. This rapidly led to the identification of optimal groups not seen in other PAPD5/7 inhibitors.
Results & conclusions: The effort culminated with the extremely potent preclinical candidate GLPG3808, which was active in an animal model of HBV infection. Progression was halted after neurological findings in a 13-week toxicological study in rat.
Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c01703 · PubMed 41557942.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Medicinal Chemistry study find?
Progression was halted after neurological findings in a 13-week toxicological study in rat.
What type of study is this?
It is a research study, published in Journal of Medicinal Chemistry in 2026. In this context, we focused on PAPD5/7 inhibitors as effective HBsAg suppressors.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acs.jmedchem.5c01703. PubMed ID: 41557942. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/discovery-and-characterization-of-glpg3808-a-papd5-7-inhibitor-for-suppr-c01703/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides